{"nctId":"NCT00316082","briefTitle":"Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","startDateStruct":{"date":"2006-06"},"conditions":["Diabetes"],"count":365,"armGroups":[{"label":"Saxagliptin 2.5 mg QAM (A)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: metformin"]},{"label":"Saxagliptin 2.5 mg titrated to 5 mg QAM (B)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: metformin"]},{"label":"Saxagliptin 5 mg QAM (C)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: metformin"]},{"label":"Saxagliptin 5 mg QPM (D)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: metformin"]},{"label":"Placebo (E)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: metformin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Placebo","otherNames":[]},{"name":"metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Inadequate blood sugar control\n\nExclusion Criteria:\n\n* Previous treatment for diabetes\n* Current treatment with other medications to lower blood sugar\n* Major heart, liver or kidney problems\n* Women who are pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1 (A1C) at Week 24","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.04","spread":"0.105"},{"groupId":"OG001","value":"7.93","spread":"0.106"},{"groupId":"OG002","value":"8.02","spread":"0.131"},{"groupId":"OG003","value":"7.79","spread":"0.112"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.30","spread":"0.106"},{"groupId":"OG001","value":"7.27","spread":"0.129"},{"groupId":"OG002","value":"7.37","spread":"0.137"},{"groupId":"OG003","value":"7.57","spread":"0.141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"0.103"},{"groupId":"OG001","value":"-0.66","spread":"0.102"},{"groupId":"OG002","value":"-0.63","spread":"0.102"},{"groupId":"OG003","value":"-0.26","spread":"0.103"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.88","spread":"0.111"},{"groupId":"OG001","value":"7.79","spread":"0.112"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.29","spread":"0.124"},{"groupId":"OG001","value":"7.57","spread":"0.141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"0.101"},{"groupId":"OG001","value":"-0.26","spread":"0.103"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Mean change from baseline in FPG at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156.6","spread":"3.96"},{"groupId":"OG001","value":"162.2","spread":"4.24"},{"groupId":"OG002","value":"170.6","spread":"6.15"},{"groupId":"OG003","value":"159.6","spread":"5.32"},{"groupId":"OG004","value":"158.6","spread":"5.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146.8","spread":"3.79"},{"groupId":"OG001","value":"151.3","spread":"5.88"},{"groupId":"OG002","value":"155.2","spread":"5.88"},{"groupId":"OG003","value":"152.4","spread":"5.88"},{"groupId":"OG004","value":"162.9","spread":"6.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"4.50"},{"groupId":"OG001","value":"-10.7","spread":"4.46"},{"groupId":"OG002","value":"-12.5","spread":"4.48"},{"groupId":"OG003","value":"-7.9","spread":"4.46"},{"groupId":"OG004","value":"3.3","spread":"4.46"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C < 7% at Week 24","description":"Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"44.9","spread":null},{"groupId":"OG002","value":"43.5","spread":null},{"groupId":"OG003","value":"38.6","spread":null},{"groupId":"OG004","value":"35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","description":"Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47432","spread":"1496.6"},{"groupId":"OG001","value":"50417","spread":"1561.5"},{"groupId":"OG002","value":"50032","spread":"1684.7"},{"groupId":"OG003","value":"47078","spread":"1941.9"},{"groupId":"OG004","value":"47640","spread":"1759.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39798","spread":"1347.0"},{"groupId":"OG001","value":"41562","spread":"1489.3"},{"groupId":"OG002","value":"41745","spread":"1739.2"},{"groupId":"OG003","value":"41530","spread":"1962.7"},{"groupId":"OG004","value":"44861","spread":"1854.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8014","spread":"1246.9"},{"groupId":"OG001","value":"-8218","spread":"1249.1"},{"groupId":"OG002","value":"-7781","spread":"1261.0"},{"groupId":"OG003","value":"-6048","spread":"1318.2"},{"groupId":"OG004","value":"-3088","spread":"1259.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":74},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","DIARRHOEA","BACK PAIN","HEADACHE"]}}}